Despite the potentiality of these nanoparticles in cancer treatment, preclinical information regarding CPN pharmacokinetic, biodistribution, overall safety upon systemic application and particularly using GBM models in animals, is scarce [9,12,13]. Here, CPN1 is linked to glioblastoma.